From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters. 2009

Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Marco Pieroni, and Qingqing Huang, and Richard B van Breemen, and Alan P Kozikowski, and Scott G Franzblau
Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, USA.

Both in vitro and in vivo metabolism studies suggested that 5-(2,8-bis(trifluoromethyl)quinolin-4-yloxymethyl)isoxazole-3-carboxylic acid ethyl ester (compound 3) with previously reported antituberculosis activity is rapidly converted to two metabolites 3a and 3b. In order to improve the metabolic stability of this series, chemistry efforts were focused on the modification of the oxymethylene linker of compound 3 in the present study. Compound 9d with an alkene linker was found to be both more metabolically stable and more potent than compound 3, with a minimum inhibitory concentration (MIC) of 0.2 microM and 2.6 microM against replicating and nonreplicating Mycobaterium tuberculosis, respectively. These attributes make 9d an interesting lead compound. A number of modifications were made to the structure of 9d, and a series of active compounds were discovered. Although some neurotoxicity was observed at a high dosage, this new series was endowed with both improved in vitro anti-TB activity and metabolic stability in comparison to compound 3.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D002522 Chlorocebus aethiops A species of CERCOPITHECUS containing three subspecies: C. tantalus, C. pygerythrus, and C. sabeus. They are found in the forests and savannah of Africa. The African green monkey is the natural host of SIMIAN IMMUNODEFICIENCY VIRUS and is used in AIDS research. African Green Monkey,Cercopithecus aethiops,Cercopithecus griseoviridis,Cercopithecus griseus,Cercopithecus pygerythrus,Cercopithecus sabeus,Cercopithecus tantalus,Chlorocebus cynosuros,Chlorocebus cynosurus,Chlorocebus pygerythrus,Green Monkey,Grivet Monkey,Lasiopyga weidholzi,Malbrouck,Malbrouck Monkey,Monkey, African Green,Monkey, Green,Monkey, Grivet,Monkey, Vervet,Savanah Monkey,Vervet Monkey,Savannah Monkey,African Green Monkey,Chlorocebus cynosuro,Green Monkey, African,Green Monkeys,Grivet Monkeys,Malbrouck Monkeys,Malbroucks,Monkey, Malbrouck,Monkey, Savanah,Monkey, Savannah,Savannah Monkeys,Vervet Monkeys
D004952 Esters Compounds derived from organic or inorganic acids in which at least one hydroxyl group is replaced by an –O-alkyl or another organic group. They can be represented by the structure formula RCOOR’ and are usually formed by the reaction between an acid and an alcohol with elimination of water. Ester
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular

Related Publications

Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Marco Pieroni, and Qingqing Huang, and Richard B van Breemen, and Alan P Kozikowski, and Scott G Franzblau
June 2007, ChemMedChem,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Marco Pieroni, and Qingqing Huang, and Richard B van Breemen, and Alan P Kozikowski, and Scott G Franzblau
January 1992, Epilepsia,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Marco Pieroni, and Qingqing Huang, and Richard B van Breemen, and Alan P Kozikowski, and Scott G Franzblau
June 2016, Trends in pharmacological sciences,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Marco Pieroni, and Qingqing Huang, and Richard B van Breemen, and Alan P Kozikowski, and Scott G Franzblau
January 2013, Current topics in medicinal chemistry,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Marco Pieroni, and Qingqing Huang, and Richard B van Breemen, and Alan P Kozikowski, and Scott G Franzblau
May 2024, Current drug discovery technologies,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Marco Pieroni, and Qingqing Huang, and Richard B van Breemen, and Alan P Kozikowski, and Scott G Franzblau
June 2019, Anti-cancer drugs,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Marco Pieroni, and Qingqing Huang, and Richard B van Breemen, and Alan P Kozikowski, and Scott G Franzblau
August 2021, Journal of medicinal chemistry,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Marco Pieroni, and Qingqing Huang, and Richard B van Breemen, and Alan P Kozikowski, and Scott G Franzblau
December 2022, European journal of medicinal chemistry,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Marco Pieroni, and Qingqing Huang, and Richard B van Breemen, and Alan P Kozikowski, and Scott G Franzblau
September 2011, Pharmacological reviews,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Marco Pieroni, and Qingqing Huang, and Richard B van Breemen, and Alan P Kozikowski, and Scott G Franzblau
January 1999, Journal of receptor and signal transduction research,
Copied contents to your clipboard!